Trial of Lixisenatide in Early Parkinson’s Disease
Authors: Wassilios G Meissner, Philippe Remy, Caroline Giordana, David Maltête, Pascal Derkinderen, Jean-Luc Houéto, Mathieu Anheim, Isabelle Benatru, Thomas Boraud, Christine Brefel-Courbon, Nicolas Carrière, Hélène Catala, Olivier Colin, Jean-Christophe Corvol, Philippe Damier, Estelle Dellapina, David Devos, Sophie Drapier, Margherita Fabbri, Vanessa Ferrier, Alexandra Foubert-Samier, Solène Frismand-Kryloff, Aurore Georget, Christine Germain, Stéphane Grimaldi, Clémence Hardy, Lucie Hopes, Pierre Krystkowiak, Brice Laurens, Romain Lefaucheur, Louise-Laure Mariani, Ana Marques, Claire Marse, Fabienne Ory-Magne, Vincent Rigalleau, Hayet Salhi, Amandine Saubion, Simon R W Stott, Claire Thalamas, Claire Thiriez, Mélissa Tir, Richard K Wyse, Antoine Benard, Olivier Rascol
Journal: New England Journal of Medicine (2024)

BackgroundLixisenatide, a glucagon-like peptide-1 receptor agonist used for the treatment of diabetes, has shown neuroprotective properties in a mouse model of Parkinson's disease.MethodsIn this phase 2, double-blind, randomized, placebo-controlled trial, we assessed the effect of lixisenatide on the progression of motor disability in persons with Parkinson's disease. Participants in whom Parkinson's disease was diagnosed less than 3 years earlier, who were receiving a stable dose of medications to treat symptoms, and who did not have motor complications were randomly assigned in a 1:1 ratio to daily subcutaneous lixisenatide or placebo for 12 months, followed by a 2-month washout period. The primary end point was the change from baseline in scores on the Movement Disorder Society–Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part III (range, 0 to 132, with higher scores indicating greater motor disability), which was assessed in patients in the on-medication state at 12 months. Secondary end points included other MDS-UPDRS subscores at 6, 12, and 14 months and doses of levodopa equivalent.Download a PDF of the Research Summary.ResultsA total of 156 persons were enrolled, with 78 assigned to each group. MDS-UPDRS part III scores at baseline were approximately 15 in both groups. At 12 months, scores on the MDS-UPDRS part III had changed by −0.04 points (indicating improvement) in the lixisenatide group and 3.04 points (indicating worsening disability) in the placebo group (difference, 3.08; 95% confidence interval, 0.86 to 5.30; P=0.007). At 14 months, after a 2-month washout period, the mean MDS-UPDRS motor scores in the off-medication state were 17.7 (95% CI, 15.7 to 19.7) with lixisenatide and 20.6 (95% CI, 18.5 to 22.8) with placebo. Other results relative to the secondary end points did not differ substantially between the groups. Nausea occurred in 46% of participants receiving lixisenatide, and vomiting occurred in 13%.ConclusionsIn participants with early Parkinson's disease, lixisenatide therapy resulted in less progression of motor disability than placebo at 12 months in a phase 2 trial but was associated with gastrointestinal side effects. Longer and larger trials are needed to determine the effects and safety of lixisenatide in persons with Parkinson's disease. (Funded by the French Ministry of Health and others; LIXIPARK ClinicalTrials.gov number, NCT03439943.) Quick Take Lixisenatide in Early Parkinson's Disease 2m 20s